Listen to “DIABETIC NERVE PAIN WILL AFFECT APPROXIMATELY 5 MILLION AMERICANS IN 2020” on Spreaker.
Find Out More About this Condition. Capsian Patch, … can be considered. a specific approved product is Qutinza
More than 34 million Americans – just over 1 in 10 – have diabetes1, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.2
The painful symptoms associated with this nerve damage include numbness, tingling, as well as shooting or stabbing sensations that most often affect the lower extremities.3
Itis a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20204 and is expected to double by 2030.5
Joining us now to discuss neuropathic pain associated with diabetic peripheral neuropathy – or diabetic nerve pain – and this newly approved treatment option is Dr. David Simpson, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City.
Key Facts and Figures:
• The lack of effective, innovative treatment options has left many patients with a significant unmet medical need.
• The condition is more common in patients with type 2 diabetes and increases with age and duration of disease.
When you book a window, we’ll provide you with guest bio & suggested questions. The interview is courtesy of Averitas Pharma, Inc.
References:
1. CDC Division of Diabetes Translation, National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html#:~:text=New%20in%202020%2C%20the%20report,1%20in%203%E2%80%94have%20prediabetes. Accessed July 6, 2020
2. University of Chicago Center for Peripheral Neuropathy. Types of peripheral Neuropathy. http://peripheralneuropathycenter.uchicago.edu/learnaboutpn/typesofpn/diabetes/diabetes.shtml. Accessed July 6,2020
3. American Diabetes Association. Peripheral NeuorapthyOverview. https://www.diabetes.org/diabetes/complications/neuropathy/peripheral-neuropathy.Accessed July 17, 2020
4. LTP2020-2030: ADDRESSABLE POPULATIONS BY CONDITION (PDPN, PSNP, PHN, CINP).Company data on file. April 30, 2020.
5. Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L.,Tai, K.-S., & Stacey, B. (2005). Pain Severity in Diabetic Peripheral Neuropathy is Associated with patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management, 30(4),374-385. doi:10.1016/j.jpainsymman.2005.04.009.
https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
6. CDC,Behavioral Risk Factor Surveillance System, 2018
7. America’sHealth Rankings. United Health Foundation.https://www.americashealthrankings.org/explore/annual/measure/Diabetes. Accessed July 13, 2020